{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:15:06Z","timestamp":1793297706966,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,20]]},"DOI":"10.1038\/s41416-026-03511-0","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:21:04Z","timestamp":1782184864000},"page":"924-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial"],"prefix":"10.1038","volume":"135","author":[{"given":"Jiajia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuiTing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-8878","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3511_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3511_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10014-4","volume":"12","author":"FL Ning","year":"2022","unstructured":"Ning FL, Lyu J, Pei JP, Gu WJ, Zhang NN, Cao SY, et al. The burden and trend of gastric cancer and possible risk factors in five Asian countries from 1990 to 2019. Sci Rep. 2022;12:5980.","journal-title":"Sci Rep"},{"key":"3511_CR3","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.4251\/wjgo.v14.i8.1528","volume":"14","author":"ZH Liu","year":"2022","unstructured":"Liu ZH, Zhu BW, Shi M, Qu YR, He XJ, Yuan HL, et al. Profiling of gene fusion involving targetable genes in Chinese gastric cancer. World J Gastrointest Oncol. 2022;14:1528\u201339.","journal-title":"World J Gastrointest Oncol"},{"key":"3511_CR4","doi-asserted-by":"publisher","first-page":"e80290","DOI":"10.1371\/journal.pone.0080290","volume":"8","author":"D Huang","year":"2013","unstructured":"Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 2013;8:e80290.","journal-title":"PLoS One"},{"key":"3511_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"3511_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41:1470\u201391.","journal-title":"J Clin Oncol"},{"key":"3511_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"key":"3511_CR8","doi-asserted-by":"crossref","unstructured":"National Health Commission of The People\u2019s Republic of China. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin. J. Cancer Res. 2022;34:207\u201337.","DOI":"10.21147\/j.issn.1000-9604.2022.03.04"},{"key":"3511_CR9","doi-asserted-by":"publisher","first-page":"S859","DOI":"10.1016\/j.annonc.2023.09.1439","volume":"34","author":"J Yuan","year":"2023","unstructured":"Yuan J, Shen L, Liu TS, Xu HT, Yang JW, Wei J, et al. Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification. Ann Oncol. 2023;34:S859\u2013S860.","journal-title":"Ann Oncol"},{"key":"3511_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2147\/OTT.S282718","volume":"15","author":"A Gordon","year":"2022","unstructured":"Gordon A, Johnston E, Lau DK, Starling N. Targeting FGFR2 positive gastroesophageal cancer: current and clinical developments. Onco Targets Ther. 2022;15:1183\u201396.","journal-title":"Onco Targets Ther"},{"key":"3511_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bjc.2013.802","volume":"110","author":"X Su","year":"2014","unstructured":"Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967\u201375.","journal-title":"Br J Cancer"},{"key":"3511_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.367","volume":"4","author":"Q Liu","year":"2023","unstructured":"Liu Q, Huang J, Yan W, Liu Z, Liu S, Fang W. FGFR families: biological functions and therapeutic interventions in tumors. MedComm. 2023;4:e367.","journal-title":"MedComm"},{"key":"3511_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925\u201335.","journal-title":"Lancet Oncol"},{"key":"3511_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke AO, Matsubara N, Park SH, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35:107\u201317.","journal-title":"Ann Oncol"},{"key":"3511_CR15","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-17-0478","volume":"23","author":"F Malchers","year":"2017","unstructured":"Malchers F, Ercanoglu M, Sch\u00fctte D, Castiglione R, Tischler V, Michels S, et al. Mechanisms of primary drug resistance in FGFR1-amplified lung cancer. Clin Cancer Res. 2017;23:5527\u201336.","journal-title":"Clin Cancer Res"},{"key":"3511_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259\u201367.","journal-title":"Clin Cancer Res"},{"key":"3511_CR17","doi-asserted-by":"crossref","unstructured":"Smyth EC, Turner N, Pearson A, Peckitt C, Chau I, Watkins D, et al. Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. J Clin Oncol. 2016;34:154.","DOI":"10.1200\/jco.2016.34.4_suppl.154"},{"key":"3511_CR18","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","volume":"28","author":"E Van Cutsem","year":"2017","unstructured":"Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28:1316\u201324.","journal-title":"Ann Oncol"},{"key":"3511_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23:1430\u201340.","journal-title":"Lancet Oncol"},{"key":"3511_CR20","unstructured":"Amgen. Amgen reports fourth quarter and full year 2025 financial results. 2025. https:\/\/www.amgen.com\/newsroom\/press-releases\/2026\/02\/amgen-reports-fourth-quarter-and-full-year-2025-financial-results?_gl=1*1uwsfvd*_up*MQ..*_ga*Mjg2Mzg2NjkyLjE3NzU4NzY2MjI.*_ga_CBMSV0J9VL*czE3NzU4NzY2MjIkbzEkZzEkdDE3NzU4NzY2NDYkajM2JGwwJGgw. Accessed April 11, 2026."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03511-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:38:37Z","timestamp":1788277117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03511-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,20]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03511-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CL, QS, LM and LS are former employees of Shanghai LianBio Development Co., Ltd. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients provided their written informed consent. The study protocol and its amendments were reviewed and approved by Medical Ethics Committee of Peking University Cancer Hospital, Medical Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School, Ethics Committee of Harbin Medical University Cancer Hospital, Ethics Committee of Zhongshan Hospital Affiliated to Fudan University, Ethics Committee of Hubei Cancer Hospital, Ethics Committee of Liaoning Cancer Hospital, Ethics Committee of the First Affiliated Hospital of Medical School of Zhejiang University, Ethics Committee of the affiliated hospital of Hebei University, Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University, Ethics Committee of Fujian Provincial Cancer Hospital, Ethics Committee of Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Ethics Committee of Henan Cancer Hospital, Ethics Committee of Fujian Cancer Hospital, Ethics Committee of the First People\u2019s Hospital of Changzhou, and Ethics Committee of Shanxi Cancer Hospital.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}